PH-102

N/A

Report date: 2025/08/20 17:35:38

Base Information

Drug NamePH-102

Drug Alias NamePH-102

ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy

Mechanisms of ActionAnti-Glypican-3

TargetsGlypican-3

Therapy Area/IndicationsCarcinoma, Hepatocellular

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited States

CombinationsNo

Global Highest StatusPreclinical

Highest Status in ChinaN/A

Originator CompaniesPowerhouse Therapeutics Inc

China Registration ClassN/A

Develop Information

Active CompaniesPowerhouse Therapeutics Inc

Inactive CompaniesN/A

Active IndicationsCarcinoma, Hepatocellular

Inactive IndicationsN/A

Other Information

ATC CodeN/A